Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NTRA is a good fit for your portfolio.
News
-
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
-
Natera Announces Real-World Data Collaboration with Merck
-
Natera Reports Third Quarter 2023 Financial Results
-
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
-
Natera to Participate in November Investor Conferences
-
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
-
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
-
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Natera, Inc.’s Directors and Officers for Breach of Fiduciary Duties – NTRA
Trading Information
- Previous Close Price
- $57.91
- Day Range
- $57.02–58.61
- 52-Week Range
- $36.20–62.99
- Bid/Ask
- $58.14 / $58.37
- Market Cap
- $7.01 Bil
- Volume/Avg
- 538,645 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.52
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3,018
- Website
- https://www.natera.com
Valuation
|
Metric
|
NTRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.79 |
Price/Sales | 6.52 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NTRA
|
|---|---|
Quick Ratio | 4.11 |
Current Ratio | 4.37 |
Interest Coverage | −41.13 |
Quick Ratio
NTRA
Profitability
|
Metric
|
NTRA
|
|---|---|
Return on Assets (Normalized) | −27.87% |
Return on Equity (Normalized) | −57.72% |
Return on Invested Capital (Normalized) | −34.14% |
Return on Assets
NTRA
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Nrfsp | $190.9 Bil | |
DHR
| Danaher Corp | Njkmrh | $161.8 Bil | |
IDXX
| IDEXX Laboratories Inc | Bmpvp | $43.4 Bil | |
IQV
| IQVIA Holdings Inc | Zqmcnff | $39.2 Bil | |
A
| Agilent Technologies Inc | Bntx | $37.6 Bil | |
MTD
| Mettler-Toledo International Inc | Zklbbz | $23.9 Bil | |
ICLR
| Icon PLC | Svszmh | $22.1 Bil | |
ILMN
| Illumina Inc | Xdcjjq | $18.6 Bil | |
LH
| Laboratory Corp of America Holdings | Thxqgk | $18.5 Bil | |
WAT
| Waters Corp | Kccq | $17.3 Bil |